Conference Coverage

Physical therapy, exercise still relevant for ankylosing spondylitis


 

REPORTING FROM SPARTAN


To combat burnout and improve patient outcomes, Mr. Papachristos suggested an alternative approach whereby patients would begin with diagnosis and medication, but disease education and a baseline fitness assessment would also be a priority. The first 6-9 months following diagnosis would then be used to evaluate a patient’s home and work/school ergonomic situation to assess needs. During this time, the patient would be introduced to basic exercises for range of motion and flexibility. Throughout this approach, the patient would be consistently reevaluated and, if appropriate, would slowly ramp up exercise efforts. At 12 months, the patients could graduate to core cervical and lumbar strength before reaching cardiovascular and sports recreation at 12-18 months following diagnosis.

Mr. Papachristos concluded that the coordination between physical therapist, primary care provider, and rheumatologist is of the utmost importance.

“It’s just like anything else – if we’re all on the same page, it’s better for the patient,” he said. “Patients should be encouraged on lifestyle and wellness management with the goal of lifelong regular exercise.”

Mr. Papachristos reported having no disclosures.

Pages

Recommended Reading

TNF inhibitors curb spinal x-ray progression in ankylosing spondylitis
MDedge Rheumatology
Role of musculoskeletal ultrasound expands in rheumatic diseases
MDedge Rheumatology
How to direct refer for GI endoscopy
MDedge Rheumatology
Arthritis limits physical activity the most in the South
MDedge Rheumatology
Maternal biologic therapy does not affect infant vaccine responses
MDedge Rheumatology
FDA approves certolizumab label update for pregnancy, breastfeeding
MDedge Rheumatology
Axial SpA disease activity remains mostly stable throughout pregnancy
MDedge Rheumatology
TB in 2017: Good news and bad news
MDedge Rheumatology
MACE risk similar across arthritis subtypes
MDedge Rheumatology
Certolizumab pegol shows promise for nr-axSpA treatment
MDedge Rheumatology